University of Miami
This purpose of this study is to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS) improves chemotherapy-induced peripheral neuropathy (CIPN) symptoms by assessing changes in daily symptom trajectories following treatment initiation. The study will also examine potential mechanisms of action through longitudinal assessment of inflammatory biomarkers, corticospinal excitability, and autonomic nervous system function.
Inclusion Criteria: 1. Age 18-80 years 2. Prior exposure to platinum, taxane, or vinca alkaloid chemotherapy 3. Glove/stocking dysesthesias ≥3 months that began after neurotoxic chemotherapy 4. Worst CIPN-related symptom ≥4/10 over the last week Exclusion Criteria: 1. Unstable cardiac disease/Known arrhythmias 2. Head or neck cancer or metastases 3. Recent ear trauma or active dermatologic disease at the stimulation site 4. \<2 months since completion of cancer treatment or surgery (i.e, tumor resection, radiation therapy, and/or taxane/platinum/vinca alkaloid chemotherapy treatments. Maint…
Participants will self-administer transcutaneous auricular vagus nerve stimulation (taVNS) using the Sparrow Link portable stimulator and flexible ear electrodes for 1 hour daily for 14 days (total stimulation time: 14 hours).The treatment stimulation intensity can be increased up to 5mA, but this will be adjusted for each participant to ensure it is below the pain threshold.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.